Kazia Therapeutics (KZIA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 6-K for Q2 FY2026, filed Mar 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KZIA SEC filings page.
Kazia Therapeutics Limited (KZIA) reported $28K in revenue for fiscal year 2025, down 98.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Financial Health Signals
We do not publish a peer-relative financial health score for Kazia Therapeutics Limited, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Kazia Therapeutics Limited passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Kazia Therapeutics Limited reported a net loss of $13.6M while operations used $8.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2026.
Cash & Balance Sheet
Kazia Therapeutics Limited held $46.3M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
None of these metrics is reported for Q2 2026.
KZIA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
KZIA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'266-K | Q4'256-K | Q2'256-K | Q4'2420-F | Q2'246-K | Q4'2320-F | Q2'236-K | Q4'2220-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $47.4M+328.1% | $4.0M-72.4% | $11.1M-33.5% | $14.4M-23.0% | $16.6M-12.1% | $18.7M-24.5% | $18.9M | $24.8M-43.1% |
| Current Assets | $46.7M+2115.1% | $3.2M-21.0% | $2.1M-61.5% | $4.1M-42.8% | $5.5M+35.8% | $7.2M+10.0% | $4.0M | $6.5M-70.4% |
| Cash & Equivalents | $46.3M+2344.1% | $2.9M+158.0% | $1.9M-22.1% | $1.1M-68.3% | $2.4M-18.6% | $3.5M-31.3% | $3.0M | $5.1M-75.4% |
| Accounts Receivable | $210K+253.9% | $64K-97.5% | $59K-97.7% | $2.6M+0.2% | $2.6M+406.7% | $2.6M+4034.5% | $504K | $63K-0.2% |
| Total Liabilities | $16.4M+22.4% | $9.4M-55.3% | $13.4M+2.9% | $21.1M+97.5% | $13.1M+18.0% | $10.7M-12.2% | $11.1M | $12.2M-19.8% |
| Current Liabilities | $16.3M+59.2% | $9.2M-46.4% | $10.2M+31.9% | $17.2M+241.7% | $7.7M+103.8% | $5.0M+8.5% | $3.8M | $4.6M-25.6% |
| Non-Current Liabilities | $182K-94.4% | $203K-94.8% | $3.2M-39.4% | $3.9M-31.3% | $5.3M-26.8% | $5.6M-24.9% | $7.3M | $7.5M-15.8% |
| Total Equity | $31.0Mn/m | -$5.5Mn/m | -$2.4M-165.5% | -$6.7M-183.3% | $3.6M-54.4% | $8.0M-36.4% | $7.9M | $12.6M-55.5% |
| Retained Earnings | -$97.1Mn/m | -$88.6Mn/m | -$77.4Mn/m | -$76.9Mn/m | -$66.9Mn/m | -$59.4Mn/m | -$55.9M | -$47.4Mn/m |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.
KZIA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
KZIA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$5.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.35), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Kazia Therapeutics Limited KZIA | FY2025 | $28K | -$13.6M | N/A | $132.2M | — |
| Compass Therapeutics, Inc. CMPX | FY2025 | $0 | -$66.5M | N/A | $141.6M | — |
| Coherus Oncology, Inc. CHRS | FY2025 | $42.2M | $168.0M | N/A | $128.3M | 31/100 |
| PDS Biotechnology Corporation PDSB | FY2025 | N/A | -$34.5M | N/A | $151.2M | — |
| Molecular Partners AG MOLN | FY2025 | $0 | -$77.7M | N/A | $137.2M | — |
| Foghorn Therapeutics Inc. FHTX | FY2025 | $30.9M | -$74.3M | N/A | $123.5M | 50/100 |
Where Kazia Therapeutics Limited Ranks
Frequently Asked Questions
Kazia Therapeutics Limited (KZIA) reported $28K in total revenue for fiscal year 2025. This represents a -98.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Kazia Therapeutics Limited (KZIA) revenue declined by 98.2% year-over-year, from $1.5M to $28K in fiscal year 2025.
No, Kazia Therapeutics Limited (KZIA) reported a net loss of $13.6M in fiscal year 2025.
Kazia Therapeutics Limited (KZIA) recorded an outflow of $8.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Kazia Therapeutics Limited (KZIA) had $4.0M in total assets as of fiscal year 2025, including both current and long-term assets.
Kazia Therapeutics Limited (KZIA) invested $4.8M in research and development during fiscal year 2025.
Kazia Therapeutics Limited (KZIA) had a current ratio of 0.35 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Kazia Therapeutics Limited (KZIA) had a return on assets of -341.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Kazia Therapeutics Limited (KZIA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $132.2M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Kazia Therapeutics Limited (KZIA) has no price-to-sales ratio at the moment: outside the range published as a multiple (on $28K revenue, FY2025). The market capitalization is $132.2M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Kazia Therapeutics Limited (KZIA) has negative shareholder equity of -$5.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Kazia Therapeutics Limited (KZIA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Kazia Therapeutics Limited (KZIA) reported a net loss of $13.6M while operations used $8.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.